Form 4: Altimmune Executive Raymond Jordt Reports Stock Transactions

Raymond Jordt, Chief Business Officer of Altimmune, Inc., reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On January 1, 2025, Raymond Jordt, Chief Business Officer of Altimmune, Inc., reported transactions involving Altimmune's common stock.
• Jordt acquired 9,375 shares of common stock through the vesting of restricted stock units (RSUs).
• Simultaneously, 2,485 shares were disposed of to cover taxes associated with the RSU vesting at a price of $7.21 per share.
• Following these transactions, Jordt directly owns 21,550 shares of Altimmune common stock and 18,750 restricted stock units.
• Jordt also has a power of attorney designating Vipin K. Garg and Gregory Weaver to act on his behalf for SEC filings.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The vesting of RSUs indicates a continued alignment of the executive's interests with the company's performance.

Future Outlook

The remaining RSUs will continue to vest in equal annual installments over the next three years, subject to continued service.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation.

Key Dates